Drug intelligence / Profile preview

thrombin

Development stage
Approved
Lead developer
Bristol Myers Squibb
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

Thrombin is a serine protease and a key enzyme in the blood coagulation cascade. It is produced from prothrombin (coagulation factor II) and functions by converting soluble fibrinogen into insoluble fibrin strands to form blood clots. Thrombin also activates several other coagulation factors (V, VIII, XI, XIII), promotes platelet activation and aggregation via protease-activated receptors on platelets, and has both procoagulant and anticoagulant roles depending on its interactions with cofactors such as thrombomodulin. Medically used forms of thrombin include those derived from human plasma (human thrombin), bovine sources (bovine thrombin), or produced recombinantly (recombinant human thrombin). These products are primarily used topically during surgical procedures to control bleeding when standard techniques are ineffective or impractical[1][2][3][4][8].

Brand names
Thrombin-JMIEVITHROMRecothrom
Other names
coagulation factor IIahuman thrombinbovine thrombinrecombinant human thrombin
02

Targets

F5 (Coagulation Factor V)F8 (Coagulation Factor VIIIa)F11 (Coagulation Factor XI)Coagulation Factor XIIIF2R (Protease-activated receptor 1)PAR2 (Protease-activated receptor 2)PAR4 (Protease-activated receptor 4)

Beyond the preview

Go deeper on thrombin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on thrombin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call